ArticleEuropean journal of heart failure2025
Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure - interaction between loss of Y chromosome and clonal haematopoiesis.
Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Relevance of Clonal Hematopoiesis in Immune Cells for Degenerative Aortic Valve Stenosis.Journal of the American Heart Association · 2026Review
- The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.Immunological reviews · 2026Review
- Cellular Senescence, Inflammaging and Cardiovascular Disease.Immunological reviews · 2026Review
- What's new in heart failure? September 2025.European journal of heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
aimsAge-associated clonal haematopoiesis of indeterminate potential (CHIP) has been linked to increased incidence and worse prognosis of chronic heart failure (CHF). CHIP arises from somatic mutations in haematopoietic stem and progenitor cells. Mosaic loss of Y chromosome (LOY), the most common somatic mutation in male blood cells, increases with age, drives clonal expansion of myeloid cells, and has been experimentally associated with cardiac fibrosis and heart failure in mice. However, its prognostic value and interplay with CHIP in CHF patients remain unclear. METHODS AND
resultsWe analysed 781 male CHF patients across the full spectrum of left ventricular ejection fraction to assess the prevalence and prognostic relevance of LOY and the two most common CHIP-driver mutations, DNMT3A and TET2. Both LOY and CHIP mutations increased with age and co-occurred in 27.1% of men >70 years. LOY independently predicted all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF). The co-occurrence of LOY and DNMT3A/TET2 mutations further increased mortality among CHIP carriers. This detrimental prognostic effect of LOY was confirmed in a validation cohort of HFrEF patients. Single-cell RNA sequencing of peripheral blood mononuclear cells from HFrEF patients with ischaemic heart failure revealed elevated pro-fibrotic signalling in LOY monocytes, characterized by increased inflammatory and remodelling markers (S100A8, TLR2, CLEC4D) and decreased expression of transforming growth factor-β inhibitors (SMAD7, TGIF2). In patients with both LOY and DNMT3A mutations, monocytes showed enhanced pro-inflammatory gene expression, including alarmins (S100A8, HMGB2) and interferon-related genes (IFNGR1, TRIM56, CD84).
conclusionsSomatic mutations in blood cells-particularly LOY-are associated with increased mortality in male CHF patients, with LOY emerging as an independent prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.